- Home
- ASMB vs CRT Comparison
ASMB vs CRT Comparison
Compare ASMB & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- CRT
- Stock Information
- Founded
- ASMB 2005
- CRT 1991
- Country
- ASMB United States
- CRT United States
- Employees
- ASMB N/A
- CRT N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- CRT Oil & Gas Production
- Sector
- ASMB Health Care
- CRT Energy
- Exchange
- ASMB Nasdaq
- CRT Nasdaq
- Market Cap
- ASMB 76.9M
- CRT 65.1M
- IPO Year
- ASMB 2010
- CRT 1992
- Fundamental
- Price
- ASMB $15.40
- CRT $9.50
- Analyst Decision
- ASMB Strong Buy
- CRT
- Analyst Count
- ASMB 3
- CRT 0
- Target Price
- ASMB $33.00
- CRT N/A
- AVG Volume (30 Days)
- ASMB 14.3K
- CRT 26.2K
- Earning Date
- ASMB 05-08-2025
- CRT 01-01-0001
- Dividend Yield
- ASMB N/A
- CRT 9.37%
- EPS Growth
- ASMB N/A
- CRT N/A
- EPS
- ASMB N/A
- CRT 0.99
- Revenue
- ASMB $32,154,000.00
- CRT $6,834,116.00
- Revenue This Year
- ASMB $33.96
- CRT N/A
- Revenue Next Year
- ASMB N/A
- CRT N/A
- P/E Ratio
- ASMB N/A
- CRT $10.02
- Revenue Growth
- ASMB 148.33
- CRT N/A
- 52 Week Low
- ASMB $7.75
- CRT $8.88
- 52 Week High
- ASMB $19.93
- CRT $14.39
- Technical
- Relative Strength Index (RSI)
- ASMB 69.79
- CRT 32.72
- Support Level
- ASMB $13.13
- CRT $9.88
- Resistance Level
- ASMB $14.35
- CRT $10.70
- Average True Range (ATR)
- ASMB 0.73
- CRT 0.27
- MACD
- ASMB 0.10
- CRT -0.03
- Stochastic Oscillator
- ASMB 84.79
- CRT 0.00
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.